Because of the low efficacy of CT approaches in HR-positive/HER2-positive BC, new chemo-free strategies are emerging; the NA-PHER2 trial evaluated the neoadjuvant use of palbociclib, fulvestrant, trastuzumab, and pertuzumab in patients with early HR-positive/HER2-positive BC with clinical objective response in 97% and 27% of pCR in enrolled patients [27]. Here, ERBB2 is linked to breast cancer.